Fennec Pharmaceuticals Inc. (FENC)

Fennec Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Net Income	-9.74	-0.44
Stock-Based Compensation	7.03	5.06
Other Adjustments	5.07	5.41
Change in Receivables	-12.44	-7.87
Changes in Inventories	-1.28	0.58
Changes in Accounts Payable	1.39	-0.54
Changes in Accrued Expenses	2.21	-0.33
Changes in Unearned Revenue	-	24.81
Changes in Other Operating Activities	-4.72	0.29
Operating Cash Flow	-12.47	26.98
Long-Term Debt Repaid	-19.48	-13
Net Long-Term Debt Issued (Repaid)	-19.48	-13
Issuance of Common Stock	44.24	1.3
Net Common Stock Issued (Repurchased)	44.24	1.3
Other Financing Activities	-2.14	-1.92
Financing Cash Flow	22.63	-13.62
Net Cash Flow	10.15	13.37
Free Cash Flow	-12.47	26.98
FCF Margin	-27.94%	56.75%
Free Cash Flow Per Share	-0.44	0.99
Levered Free Cash Flow	-31.61	11.38
Unlevered Free Cash Flow	-8.74	40.59

Updated Mar 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q